ArticleFrontiers in immunology2025
Autoimmune polyglandular syndrome among Chinese celiac disease patients: a survey of 243 individuals in China.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Distinguishing clinical features of paediatric autoimmune Addison's disease and polyendocrine syndromes: a 15-year single-centre observational study from Baghdad, Iraq.Pediatric endocrinology, diabetes, and metabolism · 2026Observational
- The "polyglandular crisis" behind recurrent hyponatremia: misdiagnosis of a case of autoimmune polyglandular syndrome type 2 and clinical lessons learned.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Celiac disease (CeD), an autoimmune enteropathy, is often associated with multiple glandular autoimmune diseases. However, the prevalence and staging characteristics of autoimmune polyglandular syndrome (APS) among CeD patients remain unclear. The aim of this study was to assess the prevalence and clinical features of APS among Chinese CeD patients. Methods: Clinical data and medical records of 243 CeD patients diagnosed in northwest China were retrospectively analyzed to identify comorbid autoimmune diseases among CeD patients. Serum interferon-ω1, interferon-α, and thyroid autoantibodies (TPOAb and TgAb) were measured, and AIRE mutations were detected. APS typing was conducted based on serum antibodies, gene sequencing (AIRE mutation analysis), and comorbidity analysis. Results: The overall prevalence of APS in CeD patients was 10.3% (25/243), and the prevalence of different types of APS varied as follows: APS-1: 0.4%, APS-2: 0.4%, APS-3: 8.2%, and APS-4: 1.2%. The prevalence of APS in CeD patients was significantly higher than that in the general population, especially the prevalence of APS-3. Patients with CeD combined with APS had a higher prevalence of vitamin D deficiency (13 of 25 patients, 52%) and Conclusion: This study is the first to systematically evaluate the prevalence and staging characteristics of APS among CeD patients, thereby filling the epidemiological data gap in this area. We emphasize the significance of screening for APS among CeD patients to enable early detection and treatment of associated autoimmune diseases and enhance patients' quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.